Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
381. |
ECCT/14/09/01 | Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa … read more |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
View |
382. |
ECCT/19/11/06 | Optimize LNG EC An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy… read more |
Principal Investigator(s) 1. Lucy Chepkurui Koech Site(s) in Kenya KEMRI/WRP Kericho |
View |
383. |
ECCT/21/05/06 | VAC52150EBL2010 ;Phase 2 An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults… read more |
Principal Investigator(s) 1. Prof. Omu Anzala Omu Anzala Site(s) in Kenya KAVI-institute of Clinical Research |
View |
384. |
ECCT/23/09/04 |
GBT440-038Open-Label Extension An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children Hospital (Nairobi… read more |
View |
385. |
ECCT/23/12/04 | GBT021601 OLE An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601… read more |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1.… read more |
View |